Lookup NU author(s): Dr Amy Kennedy,
Dr Colin Brown
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Rosuvastatin is a potent inhibitor of 3-hydroxy-3-methylglutaryl-CoA reductase and has been shown to be highly effective in reducing low-density lipoprotein cholesterol. Clinical trials have demonstrated that renal excretion and, in particular, tubular secretion, plays a role in rosuvastatin clearance. The aim of this study was to determine the involvement of the basolateral organic anion transporters, OAT1 and OAT3, in the renal uptake of rosuvastatin. Expression of human (h) OAT3 in Xenopus oocytes significantly increased the uptake of rosuvastatin above control levels (Km = 7.4 μM). In contrast hOAT1 did not mediate rosuvastatin uptake. Furthermore, hOAT3-mediated estrone-3-sulfate uptake could be inhibited, with a rank order of potency, by atorvastatin, rosuvastatin, simvastatin, and pravastatin, whereas hOAT1-mediated PAH uptake was only significantly inhibited by simvastatin. To estimate the contribution of hOAT3 to the overall renal uptake of rosuvastatin, a series of experiments were conducted using rat kidney slices. Rosuvastatin uptake in rat renal slices was abolished in the presence of the rat (r) Oat3-specific inhibitor benzylpenicillin, suggesting that rOat3 is responsible for the majority of rosuvastatin uptake across the basolateral membrane in rat kidney. From these findings, we can suggest that hOAT3 contributes to the renal uptake of rosuvastatin in humans. Copyright © 2007 by The American Society for Pharmacology and Experimental Therapeutics.
Author(s): Windass A, Lowes S, Wang Y, Brown C
Publication type: Article
Publication status: Published
Journal: Journal of Pharmacology and Experimental Therapeutics
ISSN (print): 0022-3565
ISSN (electronic): 1521-0103
Publisher: American Society for Pharmacology and Experimental Therapeutics
PubMed id: 17585018
Altmetrics provided by Altmetric